More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**Beta Finch Podcast Script - Gilead Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Gilead Sciences' first quarter 2026 results - and wow, what a quarter this was for the biotech giant.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Gilead came out swinging with some pretty impressive numbers, didn't they?

**JORDAN:** Absolutely, Alex! Let's start with the headline numbers because they're quite strong. Total product sales hit $6.9 billion, up 5% year-over-year. But here's the kicker - if you exclude their COVID drug Veklury, their base business grew 8% to $6.8 billion. That's solid growth for a company Gilead's size.

**ALEX:** And they're not just talking the talk - they're raising guidance across the board. What stood out to you most about their updated outlook?

**JORDAN:** The HIV business is absolutely on fire. They raised their HIV growth expectations from 6% to 8% for the full year, and get this - their PrEP drug Yes2Go, which prevents HIV, is now expected to hit $1 billion in sales. That would make it a blockbuster drug in just its first full year on the market!

**ALEX:** That's remarkable. Let's break down what's driving this HIV success, because it seems like Gilead is firing on all cylinders here.

**JORDAN:** It really is a multi-pronged success story. Their flagship HIV treatment Biktarvy continues to dominate with over 52% market share in the U.S. - that's a drug pulling in $3.4 billion in the quarter alone. But the real star is Yes2Go, their twice-yearly injectable HIV prevention drug. Sales jumped 72% just from the previous quarter to $166 million.

**ALEX:** And during the Q&A, management seemed pretty confident about Yes2Go's trajectory. What are they seeing that makes them so optimistic?

**JORDAN:** Great question! Johanna Mercier, their commercial chief, mentioned some really encouraging metrics. They now have 95% insurance coverage with 95% of those having zero copay for patients. They're seeing strong uptake from both people switching from other drugs and completely new users. And perhaps most importantly, the "persistency" - meaning people coming back for their second injection - is looking really good.

**ALEX:** Now, Gilead wasn't just focused on HIV this quarter. They made some major acquisition moves. Can you walk us through what they're buying and why?

**JORDAN:** This is where it gets really interesting from a strategic perspective. They closed three major deals: Arcellx for their cancer cell therapy anitocel, they're buying Tubulis for their antibody-drug conjugate technology, and Oral Medicines for autoimmune treatments. The total upfront cost? About $11.5 billion.

**ALEX:** That's a lot of cash! How are investors supposed to think about these deals?

**JORDAN:** Well, it's definitely impacting their near-term earnings - they're actually projecting a loss per share for 2026 because of these upfront costs. But management seemed confident these are strategic investments for the long term. The Arcellx deal brings them anitocel, which they believe could be best-in-class for multiple myeloma. And Tubulis gives them next-generation cancer drug technology that goes beyond their current Trodelvy franchise.

**ALEX:** Speaking of Trodelvy, how's their existing oncology business performing?

**JORDAN:** Trodelvy is growing nicely - up 37% year-over-year to $402 million. They're expecting regulatory decisions this year that could expand its use to first-line breast cancer treatment, which would be a significant ma

This episode includes AI-generated content.